The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive opinion, recommending the granting of a marketing authorisation for Desloratadine Actavis and Desloratadine ratiopharm intended for relief of symptoms associated with allergic rhinitis and urticaria.